Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTGX POWR Grades
- PTGX scores best on the Sentiment dimension, with a Sentiment rank ahead of 91.42% of US stocks.
- PTGX's strongest trending metric is Momentum; it's been moving up over the last 179 days.
- PTGX ranks lowest in Stability; there it ranks in the 6th percentile.
PTGX Stock Summary
- Of note is the ratio of PROTAGONIST THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 7.86% of US stocks have a lower such ratio.
- For PTGX, its debt to operating expenses ratio is greater than that reported by only 7.35% of US equities we're observing.
- In terms of volatility of its share price, PTGX is more volatile than 94.78% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to PROTAGONIST THERAPEUTICS INC, a group of peers worth examining would be RNA, XBIT, ENTA, CRSP, and QURE.
- Visit PTGX's SEC page to see the company's official filings. To visit the company's web site, go to www.protagonist-inc.com.
PTGX Valuation Summary
- In comparison to the median Healthcare stock, PTGX's price/sales ratio is 120.83% higher, now standing at 10.6.
- Over the past 77 months, PTGX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for PTGX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PTGX | 2022-11-25 | 10.6 | 1.5 | -2.9 | -1.7 |
| PTGX | 2022-11-23 | 10.6 | 1.5 | -2.9 | -1.7 |
| PTGX | 2022-11-22 | 11.0 | 1.6 | -3.0 | -1.8 |
| PTGX | 2022-11-21 | 11.2 | 1.6 | -3.0 | -1.9 |
| PTGX | 2022-11-18 | 11.3 | 1.6 | -3.1 | -1.9 |
| PTGX | 2022-11-17 | 11.2 | 1.6 | -3.0 | -1.9 |
PTGX Growth Metrics
- Its 3 year revenue growth rate is now at 116.04%.
- Its 5 year cash and equivalents growth rate is now at 185.51%.
- The 3 year cash and equivalents growth rate now stands at 40.51%.
The table below shows PTGX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 35.198 | -103.441 | -130.106 |
| 2022-06-30 | 45.484 | -106.71 | -132.678 |
| 2022-03-31 | 46.89 | -116.775 | -122.483 |
| 2021-12-31 | 27.357 | -107.865 | -125.551 |
| 2021-09-30 | 24.39 | -99.793 | -107.53 |
| 2021-06-30 | 27.218 | -87.61 | -81.489 |
PTGX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PTGX has a Quality Grade of D, ranking ahead of 12.65% of graded US stocks.
- PTGX's asset turnover comes in at 0.07 -- ranking 291st of 682 Pharmaceutical Products stocks.
- RGNX, MBIO, and MTEM are the stocks whose asset turnover ratios are most correlated with PTGX.
The table below shows PTGX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.070 | 1 | -0.571 |
| 2021-06-30 | 0.088 | 1 | -0.513 |
| 2021-03-31 | 0.117 | 1 | -0.538 |
| 2020-12-31 | 0.127 | 1 | -0.678 |
| 2020-09-30 | 0.140 | 1 | -0.800 |
| 2020-06-30 | 0.100 | 1 | -0.977 |
PTGX Price Target
For more insight on analysts targets of PTGX, see our PTGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $31.75 | Average Broker Recommendation | 1.44 (Moderate Buy) |
PTGX Stock Price Chart Interactive Chart >
PTGX Price/Volume Stats
| Current price | $8.07 | 52-week high | $37.04 |
| Prev. close | $7.80 | 52-week low | $6.91 |
| Day low | $7.50 | Volume | 476,000 |
| Day high | $8.16 | Avg. volume | 958,632 |
| 50-day MA | $8.15 | Dividend yield | N/A |
| 200-day MA | $12.34 | Market Cap | 397.03M |
Protagonist Therapeutics, Inc. (PTGX) Company Bio
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.
Latest PTGX News From Around the Web
Below are the latest news stories about PROTAGONIST THERAPEUTICS INC that investors may wish to consider to help them evaluate PTGX as an investment opportunity.
Protagonist Therapeutics Reports Granting of Inducement AwardProtagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2022, it issued inducement awards to Arturo Molina, M.D., M.S., F.A.C.P., the Company's recently hired Chief Medical Officer, in accordance with the terms of Dr. Molina's employment offer letter. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022. |
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 337%The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 337.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Protagonist Therapeutics Third Quarter 2022 Earnings: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021)Protagonist Therapeutics ( NASDAQ:PTGX ) Third Quarter 2022 Results Key Financial Results Net loss: US$31.2m (loss... |
Results from Protagonist Therapeutics Inc. (PTGX) show riskProtagonist Therapeutics Inc. (NASDAQ:PTGX) marked $7.71 per share on Wednesday, down from a previous closing price of $7.74. While Protagonist Therapeutics Inc. has underperformed by -0.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTGX fell by -78.29%, with highs and lows ranging from $38.11 to […] |
JMP Securities Remains a Buy on Protagonist Therapeutics (PTGX)JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX - Research Report) today and set a price target of $21.00. The company's shares closed today at $7.72.According to TipRanks, Wolleben is an analyst with an average return of -14.2% and a 27.15% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Madrigal Pharmaceuticals, and Clearside Biomedical.Protagonist Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $28.50. |
PTGX Price Returns
| 1-mo | 2.41% |
| 3-mo | -8.81% |
| 6-mo | -9.12% |
| 1-year | -74.99% |
| 3-year | -0.49% |
| 5-year | -54.33% |
| YTD | -76.40% |
| 2021 | 69.64% |
| 2020 | 185.96% |
| 2019 | 4.75% |
| 2018 | -67.64% |
| 2017 | -5.41% |
Loading social stream, please wait...